Numerous epidemiological and experimental studies have shown that patients with metabolic risk factors such as dyslipidemia, type 2 diabetes mellitus (T2DM), and homocysteinemia are more likely to develop AD, while much less is known about the role of adipokines, such as adiponectin (ADPN), in this regard (5–7). The gene discussed is ADIPOQ; the disease is metabolic syndrome.